Wednesday, 18 November 2026LatestVideosAboutContact
Latest
Brutal Assault: Youth Slaps Elderly Man Repeatedly in Just Five Seconds; Video Goes Viral!Registry Office Chaos: Fists Fly Amid Dispute Involving a Man’s Three Wives!Nepal gets nod to import 350 MW of power from India during winterPolice Encounter: Wanted Contract Killer Wahid Ansari Killed in UP's Ambedkar NagarFire destroys furniture shop in Shankarpally; no casualties reportedLeT Commander Lateef Bhat, Suspected In Kulgam CRPF Checkpost Attack, Killed After Mosque Standoff In J&KLashkar Commander: Latif Bhat Killed in Kulgam Encounter After Seven-Day OperationBiocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathwayKulgam Encounter: Lashkar Terrorist Latif Bhat Trapped Inside MosquePrime Focus' DNEG Joins Hands With Meta For 3D Cinema, Hollywood Blockbusters Set For An Immersive VR Makeover'Do Not Intend To Reinstate Him': Nvidia Board Chairman Rules Out Jensen Huang's Return As CEO, Announces Search For Permanent Successor | VideoCambridge Dictionary Names 'Human' Word Of The Year 2026 Amid Growing Concerns Over Artificial Intelligence
BusinessUpdated 17 min ago

Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway

Image: BusinessLine

The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.

Continue reading on BusinessLine

Hello Headlines links you to the original publisher for the full story.

Read full story

More in Business

See all